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Introduction
Understanding the association between epigenetic variability 
and complex exposures and disease promises an enhanced 
understanding of the risk factors for disease outcomes as well as 
the fundamental mechanisms underlying disease progression and 
biological response to key exposures.1 The array based Illumina 
Infinium HumanMethylation450K (Illumina450K) platform2,3 
is a popular technology for large scale CpG methylation profiling 
being used in most large scale population based epigenetic 
profiling studies of thousands of human individuals due to its 
comprehensive coverage and high throughput. The Illumina450K 
is designed to assess methylation levels at 485 577 individual CpG 
sites across the genome and captures a wide range of important 
genomic features.2 This platform has been successfully used to 
identify methylation marks associated with smoking,4 cancer,5,6 
aging,7 immune conditions,8 and is being employed in studies of a 
wide range of other exposures, disease outcomes, and conditions.
Despite its widespread and successful application in a 
number of studies, concerns about the technology have arisen.9-11 
Briefly, the Infinium methylation technology is built upon the 
same technology as is used for genotyping SNPs. Each probe 
infers methylation levels by capturing quantitative uracil levels 
following bisulfite conversion of the unmethylated CpGs. 
Importantly, the Illumina450K methylation array contains two 
types of probes, Type I and Type II, which differ in the manner 
through which they quantify methylation levels.12 Specifically, 
Type I probes use a common design type as the older Infinium 
HumanMethylation27 Beadchip which operate using a single 
color with two different probes to generate methylated and 
unmethylated measurements. In contrast, Type II probes use a 
single probe with two different colors to obtain the methylated 
and unmethylated measurements. The overall distribution of 
methylation values measured using Type I and Type II probes 
is different2 and it has been reported that Type II probes are 
sometimes both less reproducible and sensitive.11 While other 
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The Illumina Infinium humanMethylation450 Beadchip has emerged as one of the most popular platforms for genome 
wide profiling of DNa methylation. While the technology is wide-spread, systematic technical biases are believed to be 
present in the data. For example, this array incorporates two different chemical assays, i.e., Type I and Type II probes, which 
exhibit different technical characteristics and potentially complicate the computational and statistical analysis. several 
normalization methods have been introduced recently to adjust for possible biases. however, there is considerable 
debate within the field on which normalization procedure should be used and indeed whether normalization is even 
necessary. Yet despite the importance of the question, there has been little comprehensive comparison of normalization 
methods. We sought to systematically compare several popular normalization approaches using the Norwegian Mother 
and child cohort study (MoBa) methylation data set and the technical replicates analyzed with it as a case study. We 
assessed both the reproducibility between technical replicates following normalization and the effect of normalization 
on association analysis. Results indicate that the raw data are already highly reproducible, some normalization approaches 
can slightly improve reproducibility, but other normalization approaches may introduce more variability into the data. 
Results also suggest that differences in association analysis after applying different normalizations are not large when 
the signal is strong, but when the signal is more modest, different normalizations can yield very different numbers of 
findings that meet a weaker statistical significance threshold. Overall, our work provides useful, objective assessment of 
the effectiveness of key normalization methods.
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issues such as polymorphisms and cross reactive probes have 
arisen,10 the paramount concern seems to be in the issue of probe 
design type. The desire to address this perceived problem has 
spurred the development of a range of pre-processing and data 
normalization tools for the Infinium450K.12-15 Given the range 
of possible normalization methods, identification of the best 
normalization technique, and indeed whether normalization 
is even necessary, is a topic of great controversy and discussion 
within the field.
Despite the importance and the strong interest in the issue 
of normalization, there has been relatively little systematic 
assessment of different normalization approaches. Only recently 
has some systematic comparisons of preprocessing procedures been 
conducted.16 To further fill this critical gap in the literature, we 
compare the relative performance of four important normalization 
approaches on reproducibility using real data. Specifically, we 
examine the Illumina normalization and preprocessing method 
implemented in Illumina’s GenomeStudio software (Illumina 
Inc.), the subset-quantile within array normalization (SWAN) 
method,12 the β-mixture quantile normalization13 (BMIQ) 
method, and the complete pipeline (CP) for preprocessing 
implemented by Touleimat and Tost.14 While these methods are 
not a comprehensive catalog, they represent key approaches that 
are commonly being used. We also consider direct usage of the raw 
un-normalized data. We apply each normalization approach to a 
data set comprised of 1204 samples from the Norwegian Mother 
and Child Birth Cohort (MoBa) which contains a number of 
quality control samples and technical replicates. We then examine 
the effect of employing each method on the reproducibility of 
the measurements across technical replicates by examining key 
indicators and metrics of reproducibility. We further consider 
the ability of each approach to reduce the bias induced by usage 
of two different probe types. Finally, we examine whether the 
differences in normalized methylation measurements resulting 
from different approaches influence the subsequent association 
analysis results by examining the association between cord blood 
DNA methylation and maternal smoking during pregnancy 
within our birth cohort.
Results
Assessment of reproducibility and variability in technical 
replicates
A key objective of normalization is to remove technical 
and systematic variability from the data in order to make 
measurements comparable across samples. Therefore, we first 
investigated the ability of each normalization approach to 
reduce technical variation and improve reproducibility between 
technical duplicate pairs by examining the correlation and the 
99th Quantile of Absolute Deviation (QAD), two metrics for 
reproducibility. The correlation represents a broader metric of 
reproducibility of the CpG measurements while the 99th QAD 
seeks to characterize near worst-case behavior.
Boxplots of the pair-wise correlation between the 14 pairs of 
technical duplicates after normalization are shown in Figure 1. 
Overall, the correlation between duplicates is high for all 
normalization procedures. However, where SWAN and BMIQ 
modestly improved overall reproducibility, the CP approach 
and the Illumina normalizations actually reduced overall 
reproducibility relative to the original raw data. Figure 2 presents 
boxplots for the 99th QAD for each of the 14 duplicate pairs 
and shows that the SWAN method offers slight improvement 
(reducing the 99th QAD) over using the raw data while BMIQ 
slightly increases the 99th QAD, though the raw data also had 
the most modest range indicating that the raw data offers some 
degree of robustness. Examining the reproducibility by probe 
type, we see that the Type I probes tended to have slightly better 
reproducibility in terms of correlation and 99th QAD than Type 
II probes: the median correlations for Type I probes were all above 
99.9% for all methods except for SWAN whereas they were all 
below 99.9% for Type II probes. Interestingly, the Type I probes 
tended to be most reproducible in the original un-normalized raw 
data. Application of the SWAN and Illumina procedures reduced 
reproducibility of Type I probes while CP was, on average, 
similar to BMIQ and the raw data but the tails of the distribution 
indicate reduced reproducibility. Since Type II probes comprise 
the majority of probes on the platform (approximately two-
thirds), the results restricted to Type II probes are qualitatively 
similar to results based on all probes. These results are not driven 
by just a few duplicate pairs. In Figs. S1–6, we present line plots 
indicating that the differences observed between methods in 
the correlations and 99th-QADs are relatively uniform across 
duplicate pairs. Boxplots of the 100th and 95th QADs (Figs. S7 
and S8) are qualitatively similar to results from examining the 
99th QADs.
We separately examined the standard deviation of the 
methylation values of each CpG measurement across 12 technical 
replicates of a single adult DNA sample and 13 technical replicates 
of a second adult DNA sample after applying the normalization 
procedures considered. Since the replicates are all from a common 
sample, with perfect reproducibility the same probe would 
have the same value across all replicates such that the standard 
deviation is zero. Thus, smaller standard deviations indicate 
better reproducibility. The boxplots of the standard deviations 
of each of the 485k CpGs across the technical replicates for each 
sample are presented in Figure 3 and cumulative distribution 
functions of the standard deviations are given in Figure S9. In 
contrast to the results based on examining pair-wise correlation 
and QAD in duplicate pairs, the median standard deviation was 
overall similar across methods but somewhat lower after applying 
the CP (median SDs for Adult DNA Sample 1 and Sample 2 = 
0.012 and 0.013, respectively) and Illumina (median SDs = 0.015 
and 0.016) normalizations while the BMIQ (median SDs = 0.017 
and 0.016), SWAN (median SDs = 0.017 and 0.017), and raw 
data (median SDs = 0.019 and 0.019) had the highest overall 
variability across technical replicates. However, in examining 
the box plots in Figure 3, the height of the boxes as well as the 
large number of apparent outliers for both the CP and Illumina 
methods indicates that their distributions are wider. The 
substantially higher upper ranges and the longer tails for both 
the CP and Illumina normalizations indicate that although the 
median is slightly lower, the variability for many CP and Illumina 
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normalized probes still substantially exceeds the variability in the 
raw data and after BMIQ or SWAN normalization.
Collectively, these results indicate that the behavior of 
the average probe is improved by using the CP and Illumina 
normalizations in comparison to the BMIQ, SWAN, and raw 
data. However, the large number of probes for which variability 
is introduced by using the CP and Illumina methods impairs 
the overall reproducibility as measured through correlation 
analysis and emphasizes the near worst-case behavior measured 
through the 99th QAD. On the other hand, the BMIQ and 
SWAN normalized data tended to behave better overall, but 
this generally represented a modest improvement over using the 
original raw data. These results reflect the different characteristics 
of the individual normalization methods. The CP and Illumina 
approaches both attempt cross sample normalizations which result 
in reduced overall variability on an average sense—as seen in the 
Figure 1. Boxplots of the pairwise Pearson correlation estimates between duplicate pairs constructed using (A) all probes, (B) just Type I probes, 
and (C) just Type II probes after application of each normalization method. Note that the scale of the y-axis for the center panel is considerably narrower 
which reflects the overall better reproducibility for Type I probes.
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lower standard deviation across technical replicates. However, 
although the average behavior and overall distributions are made 
more similar, individual probes may not behave as well resulting 
in lower correlation and 99th-QAD. This is in contrast to BMIQ 
and SWAN which focus on within sample normalization. BMIQ 
directly uses the Type I probes as a reference, taking advantage 
of the strong overall reproducibility of the Type I probes, even in 
the raw data. On the other hand, SWAN still modifies the Type 
I probe values leading to better reproducibility in the Type II 
probes but reducing reproducibility of Type I probes. By further 
taking advantage of the fact that subsets of CpGs should behave 
similarly, further allows SWAN and BMIQ to remove undesired 
variability of individual CpGs.
We also examined the densities of the overall methylation 
distribution across eight randomly selected samples (Fig. S10) 
and also compared the overall distributions of probes between 
duplicate pairs via computation of the Kolmogorov-Smirnov 
statistic comparing the distance in distribution (Fig. S11). 
Figure 2. Boxplots of the pairwise 99th-QaD between duplicate pairs constructed using (A) all probes, (B) just Type I probes, and (C) just Type II probes 
after application of each normalization method. Note that the scale of the y-axis for the center panel is considerably narrower which reflects the overall 
better reproducibility for Type I probes.
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Results indicate that the CP approach makes the distributions 
between individuals more similar, but given the results above, 
this suggests that global similarity may not be sufficient for 
establishing improved reproducibility on the single CpG level.
To ensure that differences in methylation values between 
individuals are not lost due to over-normalization, we also 
examined the correlation and QAD in non-duplicate pairs. 
Figure 4 presents the pair-wise correlation in both non-duplicate 
pairs and in duplicate pairs. Overall, even for non-duplicate 
pairs, the correlation is quite high which results from the bimodal 
nature of the data. However, for each normalization procedure, 
the correlation between duplicate pairs is uniformly higher 
than correlation between non-duplicate pairs. Importantly, the 
methods that increase reproducibility between duplicate pairs 
do not seem to be reducing the differences between different 
individuals. The plots of the 99th-QAD between non-duplicate 
pairs (Fig. 4) also show that variability between individuals is 
not lost. Boxplots comparing correlation between duplicate 
and nonduplicate pairs are presented in Figures S12–16 and 
comparisons of the correlation and 99th QADs across methods 
are presented in Figures S17–20.
Bias reduction results
A secondary objective of normalization procedures for 
the Illumina 450k array is to reduce the bias that arises from 
using different probe design types. In downstream analyses, 
the difference in probe behavior can lead to differential 
representation of Type I and Type II probes among the top results 
and can adversely affect the rankings of the individual CpGs. 
Thus, we examined the degree of bias due to probe design type 
using the approach of Marabita et al.16 to consider the behavior 
of pairs of adjacent Type I and Type II probes that are within 
200 bp of each other. Nearby probes should behave similarly, 
irrespective of design type such that similarity is reflective of 
decreased bias. For two different subjects, we then plotted the 
densities of the Type I and adjacent Type II probes across two 
different subjects and after applying each of the normalization 
procedures (Fig. 5). First, we note that the raw data exhibits 
some bias which is not corrected when applying the Illumina 
normalization. We observe that the BMIQ and SWAN seem to 
best reduce the bias between the Type I and Type II probes as the 
plots lie on top of each other suggesting similarity. As with the 
results from examining reproducibility, these results makes sense 
as the BMIQ and SWAN actively seek to correct this difficulty 
while the Illumina approach does not. The CP does align the two 
modes of the Type I and Type II distributions very well, but the 
cross sample normalization may lead to too many Type II probes 
in the bottom mode. We note that following normalization, the 
overall distributions of the Type I and Type II probes are still 
different (Fig. S21).
In addition to examining the overall distribution, we also 
examine the mean absolute difference between the adjacent 
probes across 40 samples (Fig. 6). Overall, the BMIQ procedure 
tends to make nearby probes behave the most similarly, followed 
by SWAN and the CP approaches. These results are qualitatively 
similar to the results from just examining the distributions of the 
Type I and Type II probes.
Although correction for bias can be useful, we note that the 
issue of bias primarily concerns power and interpretation. Failure 
to correct for bias will affect interpretation of the results in terms 
of rankings, but if analyses are conducted at the individual 
CpG level, then the statistical analyses are still valid in terms of 
protecting the false positive rate.
Comparison of association analysis results
In addition to assessing the absolute reproducibility of the 
measurements across technical replicates and duplicate pairs, 
we also conducted an association analysis using the data under 
each normalization in order to determine if the differences 
in normalized methylation intensities lead to differences in 
downstream analysis results. Therefore, we re-analyzed the 
association between cord blood DNA methylation and maternal 
plasma cotinine4 in each of the differently normalized data sets. 
The number of CpGs that would be called significant at the 
α = 10-9, 10-7, and 10-5 levels by each method are presented 
in Table 1. These α-levels are intended to be benchmarks 
representing results in which we have differing degrees of 
confidence rather than actual recommended significance levels. 
At the most stringent levels, the results from using different 
normalizations are very similar. However, as the α-level becomes 
less stringent, differences between the methods tend to be more 
pronounced, though overall, the BMIQ, SWAN and raw data 
tended to find similar CpGs as significant which is unsurprising 
given their similar behavior in terms of reproducibility. These 
results indicate that there are some important differences 
between the methods, but for the most confident results, the 
different methods will yield similar results. Thus, if a study is well 
powered, as in the case for the MoBa analysis of maternal plasma 
Figure 3. standard deviations of the probe intensities across technical 
replicates for two different adult DNa samples after applying each nor-
malization method.
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cotinine in relation to methylation, using different methods does 
not make much difference, though this may change if the signal 
is more modest, such that interest lies in P values within more 
modest ranges.
Focusing attention on the results in which we have lower 
confidence (α = 10-5 level), we briefly examined probes that 
are significant for one method and not for another. For BMIQ, 
SWAN and using the raw data, the differences were generally near 
the borderline, i.e., the probe just (barely) met significance using 
one method and the probe just failed to meet significance using 
another method, despite being of similar orders of magnitude. In 
considering the other approaches, as we observed in the standard 
deviations across the two adult DNA samples, the overall variance 
was lower allowing for detection of considerably smaller effect 
sizes and therefore somewhat increased significance—robust 
regression reduced the influence of some outliers.
Although some methods lead to more CpGs called 
significant, it is possible that some of these may be false positives. 
Unfortunately, distinguishing false from true positives is difficult 
as this depends on the unknown true state of nature. Therefore, 
we applied a split sample strategy emulating a discovery 
experiment using half the data followed by a validation of the 
top results from the discovery phase using the second half of the 
data. Results are presented in Table 2 and indicate that although 
the CP approach calls many CpGs to be significant, many of 
these fail to validate. On the other hand, the raw data actually 
has the highest validation rate, but at the same time, the fewest 
CpGs were called significant in the discovery set. The BMIQ, 
Illumina, and SWAN approaches were all comparable in both 
the number of discovered CpGs and the number that were 
validated. The balance in validation rates and number of CpGs 
called significant in the Discovery set would seem to favor the 
BMIQ, Illumina, and SWAN methods. The overlapping number 
of validated CpGs as well as estimated validation rates under 
more modest Discovery and Validation set sizes are presented in 
Tables S1 and S2 and are qualitatively similar.
We further note that if we had used the more stringent 
Bonferroni correction within the discovery analysis (α = 10-7), 
fewer CpGs would have been called significant but a larger 
proportion of them would have been validated by all of the 
methods (Table S3). This reinforces our finding that differences 
between methods are not dramatic in terms of the results in 
which we have highest confidence.
As additional analysis, we also considered the scenario in 
which we would choose to use rankings to select the CpGs for 
validation. Briefly, for each method, we computed the validation 
rate if, instead of using a specific significance threshold in the 
discovery stage, we simply attempted to validate the top m CpGs. 
The validation rates as a function of m are given in Figure S24, 
and show that the CP method may have slightly higher validation 
rates as m increases, though for modest values of m results are all 
quite similar, again emphasizing that high confidence results do 
not depend strongly on the normalization.
Aggregating at island level
The results at the single CpG level suggest that despite some 
differences between methods, the overall reproducibility is high, 
even for the original un-normalized raw data. Any improvements 
are generally modest. Even with differences between probe 
Figure 4. (A) comparison of the distribution of pairwise Pearson correlations between duplicate pairs and non-duplicate pairs following application of 
each normalization method. correlations for non-duplicate pairs are represented by shaded boxes and are lower across all methods. (B) comparison 
of the distribution of 99th-QaDs between duplicate pairs and non-duplicate pairs following application of each normalization method. 99th-QaDs 
between non-duplicate pairs are represented by the shaded boxes and are higher across all methods.
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types, as long as analyses are conducted at the single probe level 
differences in probe type should not be strongly influential. 
However, it is possible that the need for normalization is more 
apparent when combining data across Type I vs. Type II probes. 
To examine this hypothesis, we aggregated the probes at the CpG 
island level via simple averaging and again examined the pair-
wise correlation between duplicate samples (Fig. 7) as well as the 
99th QAD and standard deviations across the two adult DNA 
samples (Figs.  S25 and 26). Results show that reproducibility 
is reduced relative to the single CpG level since variability is 
also being aggregated. The aggregated SWAN normalized data 
were the most highly reproducible while the CP normalized data 
were the least, despite also reducing the desired variability in 
non-duplicate pairs. The raw data were again comparable to the 
BMIQ normalized data and both were slightly worse than using 
SWAN. Interestingly, the Illumina method actually performed 
better for the aggregated data than the original data. Overall, 
however, results indicate that aggregating reduces reproducibility 
with SWAN being slightly superior to the other methods, though 
the differences are once again modest.
Discussion
In this study, we used a large genome wide methylation data set 
to systematically evaluate and compare the relative performance 
of using the raw un-normalized data and using the BMIQ, CP, 
Illumina, or SWAN normalized data. Specifically, we examined 
the reproducibility between technical replicates following 
application of each of the normalization procedures. We also 
compared the association analysis results from using data after 
applying each normalization. Collectively, the results based on 
examining the correlation and 99th QAD favor the use of BMIQ 
which reflects previous conclusions drawn by others.16 However, 
Figure 5. comparison of the density plots for adjacent Type I (blue lines) and Type II (red lines) probes in two different samples following application 
each normalization approach.
Figure 6. comparison of the mean absolute difference between adja-
cent Type I and Type II probes across 40 samples after applying each 
method. adjacent probes are believed to behave similarly and should 
exhibit similar distributions.
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we find the SWAN procedure to also compare favorably—
although SWAN does not perform as well on Type I, the Type 
I probes are already highly reproducible and SWAN does very 
well in increasing correlation across duplicates in Type II probes. 
Remarkably, the raw, un-normalized data are already highly 
reproducible and the improvements offered by using BMIQ 
and SWAN are modest. Both the Illumina and CP approaches 
may introduce additional variability into the data set. Results 
are similar when probes are aggregated at the CpG island level. 
In terms of probe bias reduction, BMIQ outperforms all of the 
other approaches followed by SWAN. Despite these important 
differences, the association analysis results reveal that applying 
different normalizations does not seem to make much difference 
for CpGs that are highly statistically significantly associated with 
the outcome or exposure variable, though differences are more 
apparent when the signal is weaker. When signal is weaker, the 
CP method finds more significance than other methods, but split 
sample analysis reveals that fewer CpGs validate when using the 
CP approach as well.
The strength of our work lies in the large number of technical 
replicates, which is larger than the sample sizes of many modestly 
sized experiments. This is among the first work to systematically 
compare the different normalization methods for Infinium 450K 
Methylation array in terms of both the reproducibility and the 
effect on downstream association analysis. A possible limitation 
of using a single large scale association study is the lack of a 
correspondingly large validation data set to verify the list of 
CpGs called significant in the illustrating association analysis. 
Although some two-stage analyses follow the same structure as 
our split sample strategy,17 our analysis does not exactly reflect 
a two-stage experiment using completely separate cohorts since 
both the Discovery and Validation sets were normalized together. 
This does not affect methods that only do within sample 
normalization, but for methods that consider cross-sample 
normalization, such as the CP, this means that the estimated 
validation rates may be optimistic and represent upper bounds 
(best case scenarios). In addition, due to differences in statistical 
power following each validation, failure to validate does not 
necessarily mean that individual CpGs are not associated with 
the outcome. Nevertheless, validation rate results are suggestive of 
the relative performance of the different approaches. We further 
note that in our previously published association analysis,4 we 
observed a striking degree of replication in an independent 
population when using the raw data.
Although it is true that Type II probes have greater variability, 
our results also show that both Type I and Type II probes, 
regardless of the normalization applied, are highly reproducible. 
This indicates that concerns regarding the issue may be 
somewhat over-inflated, particularly in light of our association 
analysis results. This also makes intuitive sense since single 
CpG based analyses will only focus on a single probe type at a 
time. Multi-CpG analyses will simultaneously test the effect of 
multiple probes (including probes of different design type), but 
any statistically valid method will automatically accommodate 
differences in variability. That said, however, assessment 
of whether the methylation values of different probe types 
actually reflect the underlying methylation level is challenging. 
Spike-in experiments or simultaneous application of alternative 
methylation platforms would be necessary.
The emphasis of our work is primarily on examining 
reproducibility, which from the perspective of many biomedical 
studies is of paramount importance. Consequently, we do not 
Table 1. Overlapping numbers of significant cpGs at each significance level α based on regressing percent methylation of each cpG on cotinine level 
using robust linear regression model with sandwich estimators of the covariance for P value calculation
BMIQ CP Illumina SWAN Raw
α = 10-9
BMIQ 27 26 25 26 25
cP 31 25 25 24




BMIQ 37 34 30 31 29
cP 52 30 32 29




BMIQ 156 108 92 97 94
cP 462 107 90 83
Illumina 207 96 86
sWaN 148 83
Raw 105
Each number corresponds to the number of cpGs called significant at the particular α-level by both the method at the top of the table and the method 
at the left side of the table. aThis differs slightly from the number found in the original analysis4 since the current analysis uses percent methylation as the 
outcome and further adjusts for season of birth.
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explore additional issues such as SNPs within the methylation 
probes as well as probes that map to multiple regions of the 
genome as they should be reproducible between technical 
replicates. Appropriate methods for assessing these features are 
important for interpretation of results and for quality control, but 
remain outside the scope of the present work.
Recently, sequencing based technologies for genome wide 
epigenetic profiling have emerged. While such technology may 
be able to better capture true methylation levels with higher 
resolution, such new technologies will undoubtedly present 
additional analytical and computational challenges. Combined 
with high costs we anticipate that the array based Infinium 
450k Methylation platform will remain a popular technology for 
large scale CpG methylation profiling. Therefore, our results are 
reassuring in that despite some technical concerns, overall, the 
technology is highly reproducible and can yield results that are 
trustable, irrespective of the normalization procedure used
Methods
Normalization methods
The normalization methods considered in this work are: the 
Illumina normalization and preprocessing method implemented 
in Illumina’s GenomeStudio software (Illumina Inc.), the 
subset-quantile within array normalization (SWAN) method,12 
the β-mixture quantile normalization13 (BMIQ) method, and 
the complete pipeline (CP) for preprocessing implemented by 
Touleimat and Tost.14 We briefly describe each method.
For each sample, the raw methylation value for each CpG is 
defined as b = M/(M + U + 100) where M and U are the intensities 
of the methylated and unmethylated probes, respectively. No 
processing, background subtraction, or normalization was done. 
The raw values we used were obtained directly exported from the 
GenomeStudio18 work space.
The Illumina normalization method is an optional 
normalization approach provided within GenomeStudio and 
separately implemented within the minfi19 Bioconductor 
package.20 The approach involves background subtraction 
which is intended to reduce variability between arrays due to 
differences in background levels and is accomplished by using 
negative control probes: probes that are thermodynamically 
equivalent to regular probes but that do not target specific parts 
of the transcriptome. Separate normalization to internal controls 
is accomplished by rescaling the probes for each sample such 
that the control probes have a common mean across samples. 
Methylated and unmethylated probes are normalized separately. 
We directly use the normalization implemented with the minfi 
package.
The SWAN method specifically addresses the bias and 
variability within each sample that arises from the different 
chemistry and design of Type I and Type II probes. SWAN 
assumes that conditional on the number of CpGs within the 
probe (an approximate reflection of its biological importance), the 
distribution of probe intensities should be the same. Consequently, 
subset quantile normalization can be used to enforce distributions 
to be similar. The SWAN adjusted intensities reduces technical 
differences between Type I and Type II probes within each array. 
No between array normalization is done.
As with the SWAN method, the BMIQ approach recognizes 
the differences in intensity due to probe design type and focuses 
on within sample normalization. The approaches focuses on 
transforming the only distribution of Type II probes to be similar 
to the Type I probes. Briefly, individual probes (of both types) 
on a sample are assigned to be methylated, hemi-methylated, 
and unmethylated. Then the Type II probes classified as 
methylated or unmethylated are quantile normalized to have 
identical distribution as the Type I probes of the corresponding 
class. Each hemi-methylated Type II probes is then location and 
scale adjusted to span the range between the methylated and 
unmethylated Type II probes.
The CP approach is an attractive method that comprehensively 
pre-processes the data through a sequence of steps that includes 
background subtraction and color bias correction, and within 
and across sample quantile normalization. Conveniently, the 
software also implements extensive quality control procedures 
including filtering of results based on the detection p-values, 
number of beads, and other probe characteristics such as presence 
of SNPs. The normalization focuses on using a subset quantile 
normalization to normalize the Type I probes and the Type I 
probes separately, with probes first divided into categories probe 
annotations and intelligently selected anchors for computing the 
reference distributions of the Type I and Type II probes.
MoBa methylation data
The Norwegian Mother and Child cohort (MoBa) enrolled 
over 100 000 women between 1999 and 2008 and has been 
described in detail elsewhere.21,22 The MoBa methylation study 
is an epigenetic profiling study within the broader MoBa birth 
cohort. Overall, epigenetic profiling of 1204 DNA samples was 
performed: in addition to cord blood DNA collected from 1131 
singleton live births, additional duplicate and replicate samples 
were also generated. This included 13 pairs of technical duplicate 
samples from the infant cord blood samples as well as 2 adult DNA 
samples which were each replicated 13 times. The remaining 
samples consisted of additional cell line and quality control 
samples. For each sample, DNA methylation at 485 577 cytosine 
positions (CpG sites) was measured using the Illumina Infinium 
HumanMethylation450 BeadChip.2,3 Bisulfite conversion was 
Table 2. The number of significant cpGs in the discovery set, the valida-
tion set, and the percentage of cpGs that are validated for each normaliza-
tion procedure
BMIQ CP Illumina SWAN Raw
Discovery 34 290 39 33 22
Validation 21 30 21 22 19
Proportion validated 62% 10% 54% 67% 86%
significance for Discovery was determined at the Benjamini-hochberg 
FDR = 5% level. These cpGs were validated in the Validation set. cpGs sig-
nificant in the Validation set following Bonferroni adjustment for the num-
ber of significant Discovery cpGs are considered to be validated. Note that 
validation rates are considered upper bounds (best case) for methods that 
apply cross sample normalization since discovery and validation samples 
were jointly normalized.
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performed using the EZ-96 DNA Methylation kit according to 
manufacture instructions (Zymo Research Corporation) and 
checked per methods previously described.2
We applied each of the four normalization approaches to the 
full 1204 samples from the MoBa study. In addition to these 
normalization approaches, we also considered the reproducibility 
of using the raw, un-normalized data (denoted as Raw). For each 
method, we used the standard defaults implemented within the 
corresponding software packages.
Following normalization, we conducted quality control (QC) 
of the data as previously described.4 Detection p-values and 
multidimensional scaling were used to identify erroneous samples 
and CpGs were excluded based on missing data and genomic 
position. Specifically, after omitting samples with potential 
gender mismatch probes with detection P values greater than 10-5 
were set to be missing. The CP approach includes additional built 
in QC that allowed for further filtering of probes with fewer than 
3 beads. Samples with more than 5% of the CpGs missing were 
omitted such that 1068 of the 1131 infant DNA samples and 12 
of 13 duplicate infant DNA pairs were available for analysis. In 
addition, 12 of 13 replicates of the first adult DNA sample and all 
13 replicates of the second adult DNA sample survived QC and 
were available for analysis.
Assessing reproducibility in technical replicate samples
Our main approach for assessing reproducibility between pairs 
of replicates is to examine the reproducibility between pairs of 
technical replicates and the variation across technical replicates. 
Since the objective is to improve reproducibility, increased 
similarity between technical replicates and reduced variability 
between replicates are hallmarks of attractive normalization 
procedures.
We first assessed reproducibility by examining the Pearson 
correlation between pairs of duplicate samples. Since Pearson 
correlation measures similarity between two different sets of 
measurements, we can use this to examine similarity between 
duplicates. Thus, we randomly paired two of the replicate DNA 
samples for the first adult DNA sample and we separately paired 
two of the replicate DNA samples for the second adult DNA 
sample. Combined with the 12 infant duplicate samples, this 
yields a total of 14 pairs (28 samples) of technical duplicates. 
For each pair, we compute the standard Pearson correlation to 
obtain 14 correlations for each normalization method – since our 
objective is purely relative correlation the non-normality is not 
of concern. Higher Pearson correlation is indicative of improved 
reproducibility. Since the data are bimodal at zero and one, the 
correlation is necessarily high and should not be interpreted as an 
absolute measure but rather as a relative measure, which is our 
objective.
Although correlation is useful for obtaining an assessment of 
overall reproducibility, we are also interested in quantifying near 
“worst case” behavior since we want all of the data to be well 
normalized—not just the average case. Consequently, we also 
examined the Quantile of Absolute Difference (QAD) between 
duplicates. For any pair of samples, the qth QAD is found by 
computing the difference in methylation level for each probe, 
calculating the absolute value to obtain the absolute difference, 
and then determining the qth percentile of the absolute difference. 
The number q is between 0 and 100 and corresponds to the qth 
Figure 7. (A) Pairwise Pearson correlation between cpG island level aggregate values for duplicate pairs (B) comparison of the distribution of pairwise 
Pearson correlations between cpG island level aggregate values duplicate pairs and non-duplicate pairs following application of each normalization 
method. correlations for non-duplicate pairs are represented by shaded boxes and are lower across all methods.
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percentile of the absolute difference with 0 representing the 
minimum and 50 the median. Setting q to be 100 corresponds 
to assessing the reproducibility between a pair of replicates by the 
maximum absolute difference which corresponds to the absolute 
worst case. However, since this can be driven by a single outlier, 
we instead would set q to be a large number less than 100 in 
order to accommodate a few poorly performing probes while 
still assessing the near worst case behavior of each normalization 
method. In general, the QAD is useful metric for assessing 
reproducibility as it measures the dissimilarity between pairs of 
replicates. For each normalization method, we assessed the 99th 
QAD for each duplicate pair to obtain the 14 QADs. Since larger 
QADs correspond to larger differences between pairs of samples, 
a lower QAD is indicative of better reproducibility.
In addition to looking at reproducibility in duplicate pairs, we 
also examined across technical replicates in the 12 replicates of 
the first adult DNA sample and the 13 replicates of the second 
adult DNA sample. Briefly, for each of the CpGs in the study, we 
calculated the standard deviation in the methylation value across 
replicates. This was done separately for each of the two adult DNA 
samples in the study. The standard deviation is a direct measure 
of variability among a group of measurements. Since the subjects 
are all technical replicates, smaller standard deviations for each 
CpG, corresponding to lower variability, are representative of 
better reproducibility. Note that for each normalization method 
and adult DNA sample, we have a distribution of 485k standard 
deviations rather than single numbers.
Examination of non-replicate samples
Although reproducibility is the key metric for assessing 
preprocessing procedures, we also are interested in ensuring 
that the differences between individuals are not subsequently 
lost. Over-normalization would lead to reproducible data sets 
which would still allow for valid down-stream analysis, but at 
the expense of reduced power. To examine whether the methods 
that improve reproducibility are also removing inter-individual 
variability, we examined the same reproducibility metrics for 
duplicate pairs within non-duplicate pairs. For each of the 14 
pairs of duplicate samples, we break the pairs and randomly pair 
each sample with a different sample. We then apply the same 
reproducibility metrics to the non-duplicate pairs.
Examination of probe design bias
In addition to examining reproducibility, another important 
metric for assessing preprocessing procedures lies in determining 
whether some procedures can reduce the bias between probe 
design types: essentially, does the measure methylation level well 
reflect the true methylation level and the associated variability. 
Therefore, we follow a similar approach used by others16 to 
compare the bias across different methods. The logic behind the 
approach is that CpGs in close proximity should share similar 
characteristics in terms of epigenetic relevance and should behave 
similarly irrespective of probe design type. To exploit this, we 
identified pairs of adjacent probes which are of differing design 
type, i.e., one Type I probe and one Type II probe. For each 
sample, we then examined the distribution of the Type I probes 
and the Type II probes comprising the pairs. Similarity in the 
distribution of Type I and Type II probes represents improved 
bias reduction. Separately, we also calculated the mean absolute 
difference between the probe pairs for each sample. Since we 
anticipate adjacent CpGs behaving similarly, a lower mean 
absolute difference is suggestive of lower bias.
Analysis of cotinine exposure data in the MoBa study
Using the 1062 infant samples on which we had complete 
covariate information, for each of the normalized data sets, we 
evaluated the association between plasma cotinine levels and 
methylation in cord blood at each of the CpG sites, one-at-
a-time, using a similar approach as in the original analysis of 
these data4. Specifically, using the methylation β values as the 
dependent variable and the plasma cotinine as the predictor, we 
applied robust linear regression with sandwich-based estimators 
of the covariance in order to accommodate potential outliers 
and heteroskedasticity to compute a P value for each CpG. We 
adjusted for child sex, maternal parity, maternal age, folate,23 
asthma, and season of birth as potential confounders. Note that 
this analysis differs from the original analysis of these data in 
that we used the methylation β values and we further adjusted 
for season of birth. We compared the number of probes that 
would be called significant by each of the methods at α = 10-5, 
10-7, 10-9 levels, noting that 10-7 approximately corresponds to 
Bonferroni significance.
A limitation of using real data analysis results to compare 
methods is that the CpGs called significant may be false 
positives such that identification of more significant results 
is not necessarily indicative of a better approach. In general, 
determining false positives is difficult since it is unknown which 
probes are false positives, a priori. Therefore, we considered 
an alternative analysis to shed light on whether significant 
CpGs are false positives using a split sample strategy. Briefly, 
after applying each normalization approach, we split each of 
the normalized data sets into two equal data sets, treating half 
of the data as “Discovery” and half as “Validation.” We then 
analyzed the Discovery set using the same statistical tests as used 
previously in the analysis of the full (pooled) data set of 1062 
samples and we identify the CpGs significant at the more liberal 
0.05 Benjamini-Hochberg false discovery rate (FDR) level.24 
We then attempted to validate each of the significant CpGs 
using the Validation set by again applying the same statistical 
analyses, except we controlled significance via the more 
stringent Bonferroni correction—note that the exact α-level 
for each method differs depending on the number of probes 
called significant in the Discovery set. We did this for each of 
the normalized data sets (splitting the subjects in the same way 
for each data set). The proportion of CpGs significant in the 
validation set is determined to be the validation rate. Ideally, 
a higher validation rate is suggestive (though not perfectly so) 
of lower false positive rate in the Discovery set. This analysis 
exactly replicates the Validation-Discovery process used in some 
split-sample analyses,17 but differs from Validation-Discovery 
processes that use two independent groups of subjects. This 
is due to the fact that the Validation and Discovery sets were 
normalized together such that for methods that do cross sample 
normalization, estimated validation rates are slightly more 
optimistic.
www.landesbioscience.com Epigenetics 329
Assessing reproducibility in data aggregated at the CpG 
island level
When focusing on individual CpG analysis, wherein the 
CpGs are analyzed one-at-a-time, differences between probes 
in terms of design type may not play a large role since one is 
not comparing across probes. However, the result of differences 
between probe types may become more apparent if analyses are 
aggregated over CpGs measured with probes of different design 
type. To examine this hypothesis, we considered the 24 928 CpG 
islands comprised of more than 5 CpGs. Then for each sample 
we aggregated the CpGs within each island by simply averaging 
the CpG intensities to obtain 24 928 values. We then examined 
the reproducibility of these averaged methylation values by again 
computing the Pearson correlation and 99th-QAD between 
the same duplicate pairs as before. We acknowledge that simple 
averaging may not be the best way for aggregating values, but 
still serves as a qualitatively useful measure when examining 
reproducibility.
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